USPTO serial 79400685
PACE (PATHWAYS TO ANTIMICROBIAL CLINICAL EFFICACY)
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- GALBO, AMANDA
- Law office
- TMO LAW OFFICE 125
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with PACE (PATHWAYS TO ANTIMICROBIAL CLINICAL EFFICACY)?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Promoting research in the field of human health and human diseases through the support and coordination of research projects conducted by universities, hospitals, research foundations and businesses; providing advisory, consultancy and information services in the field of commercialisation of products and services by identifying routes to market for research; compilation of scientific, medical and clinical information; maintenance, namely updating of information in databases in relation to medical and health research. | ACTIVE | — |
| 036 | Charitable fund raising; charitable collections; organisation of collections; provision of funding for research, education, prevention and treatment of illnesses and human diseases; financial grant services; provision of funding for charities; provision of funding for medical trials; provision of funding for educational and research posts; information and advisory services relating to all the aforesaid; technology transfer services, namely assisting technologies inventors secure appropriate funding to take development forward; technology transfer services, namely managing revenue from partnered or developed intellectual property; all of the aforesaid in relation to medical and health research. | ACTIVE | — |
| 042 | Scientific, medical and clinical research services, biotechnology research and analysis, biochemical research and analysis, biological research and analysis, clinical trials, data mining in relation to medical and health research, data security services in relation to medical and health research, data encryption services in relation to medical and health research, database design and development in relation to medical and health research, mathematical modelling in relation to medical and health research, bioinformatics, drug discovery services, laboratory research, computer programming and design services in relation to medical and health research; consultancy services relating to all of the foregoing; scientific research and development in the field of medical technology; research on the development and adaptation of health technology and health-related outcomes associated with implementation of health technology; clinical research services, namely, collection, calibration, analysis and reporting of data in connection with clinical trials; conducting clinical trials for diagnostic tests and for pharmaceutical preparations; providing temporary use of non-downloadable web-based computer software for data integration, exchange, and analysis in relation to medical and health research; providing biomedical and scientific information via a global internet web site related to the field of human health and human diseases; technology transfer services namely product design and development, research and development, product development in relation to medical and health research; antibody humanisation services, namely antibody engineering; biopharmaceutical development; biologic assay development; preclinical research; clinical research; clinical trials management; pharmacovigilance, namely monitoring the effects of medical drugs after they have been licensed for use. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 19, 2026 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 5, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 5, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 8, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 24, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 24, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 5, 2025 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 5, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 7, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 9, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 19, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 17, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 8, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 7, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 29, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 29, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 25, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |